Open AccessMexiletine in Myotonic Dystrophy Type 1
Author(s) -
Chad Heatwole,
Elizabeth Luebbe,
Spencer Rosero,
Katy Eichinger,
William Martens,
James E. Hilbert,
Jeanne Dekdebrun,
Nuran Dilek,
Christine Zizzi,
Nicholas Johnson,
Araya Puwanant,
Rabi Tawil,
Giovanni Schifitto,
Christopher A. Beck,
J. Franklin Richeson,
Wojciech Zaręba,
Charles A. Thornton,
Michael P. McDermott,
Richard T. Moxley
Publication year - 2021
Publication title -
neurology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.91
H-Index - 364
eISSN - 1526-632X
pISSN - 0028-3878
DOI - 10.1212/wnl.0000000000011002
Subject(s) - mexiletine , medicine , myotonia , myotonic dystrophy , placebo , anesthesia , qt interval , cardiology , cohort , physical therapy , pathology , alternative medicine
To assess mexiletine's long-term safety and effect on 6-minute walk distance in a well-defined cohort of patients with myotonic dystrophy type 1 (DM1).